Department of Oncology and Pathology, Karolinska Institutet and University Hospital, Stockholm, Sweden.
Department of Radiation Oncology, Stanford School of Medicine, Stanford, CA, USA.
Oncogene. 2020 Aug;39(32):5430-5440. doi: 10.1038/s41388-020-1367-4. Epub 2020 Jun 24.
Pan-cancer genomic analyses based on the magnitude of pathway activity are currently lacking. Focusing on the cell cycle, we examined the DNA mutations and chromosome arm-level aneuploidy within tumours with low, intermediate and high cell-cycle activity in 9515 pan-cancer patients with 32 different tumour types. Boxplots showed that cell-cycle activity varied broadly across and within all cancers. TP53 and PIK3CA mutations were common in all cell cycle score (CCS) tertiles but with increasing frequency as cell-cycle activity levels increased (P < 0.001). Mutations in BRAF and gains in 16p were less frequent in CCS High tumours (P < 0.001). In Kaplan-Meier analysis, patients whose tumours were CCS Low had a longer Progression Free Interval (PFI) relative to Intermediate or High (P < 0.001) and this significance remained in multivariable analysis (CCS Intermediate: HR = 1.37; 95% CI 1.17-1.60, CCS High: 1.54; 1.29-1.84, CCS Low = Ref). These results demonstrate that whilst similar DNA alterations can be found at all cell-cycle activity levels, some notable exceptions exist. Moreover, independent prognostic information can be derived on a pan-cancer level from a simple measure of cell-cycle activity.
目前缺乏基于通路活性程度的泛癌症基因组分析。我们聚焦于细胞周期,在 32 种不同肿瘤类型的 9515 名泛癌症患者中,检查了低、中、高细胞周期活性肿瘤中的 DNA 突变和染色体臂水平非整倍性。箱线图显示,细胞周期活性在所有癌症中广泛变化。TP53 和 PIK3CA 突变在所有细胞周期评分(CCS)三分位中都很常见,但随着细胞周期活性水平的增加而频率增加(P<0.001)。BRAF 突变和 16p 增益在 CCS 高肿瘤中较少见(P<0.001)。在 Kaplan-Meier 分析中,与中或高 CCS 相比,CCS 低肿瘤患者的无进展生存期(PFI)更长(P<0.001),并且这一意义在多变量分析中仍然存在(CCS 中:HR=1.37;95%CI 1.17-1.60,CCS 高:1.54;1.29-1.84,CCS 低=参考)。这些结果表明,虽然在所有细胞周期活性水平都可以发现类似的 DNA 改变,但存在一些明显的例外。此外,从细胞周期活性的简单测量中,可以在泛癌症水平上获得独立的预后信息。